Online inquiry

IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3807MR)

This product GTTS-WQ3807MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets NCAM1 gene. The antibody can be applied in Small Cell Lung Cancer (SCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000615.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4684
UniProt ID P13591
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3807MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6967MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ4711MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-986168
GTTS-WQ438MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 3C23K
GTTS-WQ14867MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ13726MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RC48-0
GTTS-WQ12974MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ10426MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY2439821
GTTS-WQ3376MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AT-005
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW